<DOC>
	<DOC>NCT01380730</DOC>
	<brief_summary>To evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab (AMG 145) administered every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on percent change from baseline in LDL-C when used in addition to a statin in adults with hypercholesterolemia.</brief_summary>
	<brief_title>LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Male or female ≥ 18 to ≤ 80 years of age On an approved statin, with or without ezetimibe, with stable dose(s) for at least 4 weeks Fasting LDLC ≥ 85 mg/dL Fasting triglycerides ≤ 400 mg/dL Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization Type 1 diabetes; newly diagnosed or poorly controlled type 2 diabetes (Glycosyated Hemoglobin (HbA1c) &gt; 8.5%) Uncontrolled hypertension New York Heart Association (NYHA) III or IV heart failure, or known left ventricular ejection fraction &lt; 30% Uncontrolled cardiac arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Proprotein convertase subtilisin/kexin type 9 (PCSK9)</keyword>
</DOC>